a group of drugmakers, public health organizations and doctors said in a letter to US lawmakers on Tuesday, urging Senators to take a fresh approach to stimulate antimicrobial drug development by enacting policy measures to increase the value of a marketed antibiotic. Beyond the incentives already in place to push drugmakers to develop antibiotics, the group urged the passage of “pull incentives,” or policy measures to increase the value of a marketed antibiotic by rewarding drugmakers only after their antibiotic is approved by the FDA.
IMO, Leo should wait on more lucrative "pull incentives" before advancing B-absssi into a P3. B has lots of other indications (OM, IBD, etc) that he can work on bringing to market in the meantime.